Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, December 21, 2021 12:59:35 AM
The biotech stands to reap hundreds of millions of dollars from a new collaboration with a top pharmaceutical player.
https://www.fool.com/investing/2021/12/20/why-lineage-cell-therapeutics-zoomed-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Eric Volkman
(TMFVolkman)
Dec 20, 2021 at 6:03PM
Author Bio
What happened
Clinical-stage biotech Lineage Cell Therapeutics (NYSEMKT:LCTX) was a bright spot during a dark session for the overall stock market. The company's shares rocketed upward by more than 21% on Monday on news of a collaboration agreement with a large and deep-pocketed partner.
So what
On Monday morning, Lineage disclosed that it and its Cell Cure Neurosciences subsidiary had signed a global collaboration and licensing deal with two units of Swiss healthcare powerhouse Roche Holding (OTC:RHHBY).
The deal covers the development and potential commercialization of its retinal pigment epithelium (RPE) cell therapy for the treatment of certain eye disorders. Such maladies include advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).
Specifically, Roche's Genentech subsidiary is to manage the continued clinical development and commercialization of OpRegen, which utilizes RPE to treat afflictions like dry AMD. OpRegen is Lineage's leading -- and most promising -- pipeline program. It's currently undergoing testing in a phase 1/2a clinical trial.
Lineage is to receive a $50 million upfront payment from Genentech. The biotech will also be eligible for up to $620 million in additional payouts if certain development, regulatory, and business milestones are met. It did not provide any detail about those milestones. Finally, Lineage will also be eligible for tiered, double-digit-percentage royalties on sales of the treatment.
Now what
For Lineage, this Roche deal is a juicy opportunity to not only bring OpRegen to market, but to advance its wider mission.
"Lineage's objective is to pioneer a new branch of regenerative medicine, based on transplanting whole cells into the body to restore activity lost to aging, injury or disease," CEO Brian Culley said in the press release announcing the deal. "We believe the results we have demonstrated to date with OpRegen represent a paradigm change many did not believe possible with cell therapy, by restoring retinal tissue and potentially halting or reversing the expansion of geographic atrophy."
Recent LCTX News
- Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop • Business Wire • 09/18/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 10:24:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:10:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:30:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 01:11:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/15/2024 04:15:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:39:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2024 08:36:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:10:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 10:17:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:10:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:30:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:27:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 11:58:18 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/08/2024 11:57:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/06/2024 02:25:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:20:38 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM